Skip to main content

Table 3 Associations of differences between Δage (per 5 years) according to different predictors of DNAmage with all-cause and cause-specific mortality by sex

From: Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a German case cohort

 

Number of events; %

Predictor

Cox model 1a

(Hazard ratios)

Cox model 1b

(Hazard ratios)

All-cause mortality

    

Women

251; 41.7

DNAmage (Horvath)

1.27 (1.07–1.52)

1.24 (1.02–1.52)

  

DNAmage (Hannum)

1.19 (0.94–1.51)

1.05 (0.82–1.36)

Men

351; 58.3

DNAmage (Horvath)

1.23 (1.05–1.43)

1.28 (1.09–1.51)

  

DNAmage (Hannum)

1.14 (0.94–1.40)

1.14 (0.92–1.41)

Cancer mortality

    

Women

95; 40.4

DNAmage (Horvath)

1.20 (0.93–1.54)

1.21 (0.88–1.65)

  

DNAmage (Hannum)

1.02 (0.69–1.50)

0.89 (0.58–1.36)

Men

140; 59.6

DNAmage (Horvath)

1.18 (0.95–1.47)

1.25 (0.98–1.59)

  

DNAmage (Hannum)

1.08 (0.80–1.46)

1.12 (0.79–1.58)

CVD mortality

    

Women

80; 41.2

DNAmage (Horvath)

1.17 (0.91–1.51)

1.13 (0.82–1.55)

  

DNAmage (Hannum)

1.21 (0.85–1.72)

1.01 (0.64–1.61)

Men

114; 58.8

DNAmage (Horvath)

1.25 (0.98–1.59)

1.29 (0.99–1.68)

  

DNAmage (Hannum)

1.06 (0.77–1.47)

1.00 (0.71–1.42)

  1. CVD cardiovascular disease
  2. aModel 1: adjusted for chronological age (continuous), sex, batch effects, and leucocyte distribution
  3. bModel 2: additionally adjusted for educational level, history of cancer diseases, history of CVD, hypertension, diabetes mellitus, smoking status (never/former vs. current), and Body Mass Index (continuous)